A novel microRNA signature for the detection of melanoma by liquid biopsy.
Biomarkers signature
Diagnosis
Extracellular vesicles
Liquid biopsy
Melanoma
microRNAs
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
15 10 2022
15 10 2022
Historique:
received:
15
07
2022
accepted:
25
09
2022
entrez:
15
10
2022
pubmed:
16
10
2022
medline:
19
10
2022
Statut:
epublish
Résumé
Melanoma is the deadliest form of skin cancer and metastatic disease is associated with a significant survival rate drop. There is an urgent need for consistent tumor biomarkers to scale precision medicine and reduce cancer mortality. Here, we aimed to identify a melanoma-specific circulating microRNA signature and assess its value as a diagnostic tool. The study consisted of a discovery phase and two validation phases. Circulating plasma extracellular vesicles (pEV) associated microRNA profiles were obtained from a discovery cohort of metastatic melanoma patients and normal subjects as controls. A pEV-microRNA signature was obtained using a LASSO penalized logistic regression model. The pEV-microRNA signature was subsequently validated both in a publicly available dataset and in an independent internal cohort. We identified and validated in three independent cohorts a panel of melanoma-specific circulating microRNAs that showed high accuracy in differentiating melanoma patients from healthy subjects with an area under the curve (AUC) of 1.00, 0.94 and 0.75 respectively. Investigation of the function of the pEV-microRNA signature evidenced their possible immune suppressive role in melanoma patients. We demonstrate that a blood test based on circulating microRNAs can non-invasively detect melanoma, offering a novel diagnostic tool for improving standard care. Moreover, we revealed an immune suppressive role for melanoma pEV-microRNAs.
Sections du résumé
BACKGROUND
Melanoma is the deadliest form of skin cancer and metastatic disease is associated with a significant survival rate drop. There is an urgent need for consistent tumor biomarkers to scale precision medicine and reduce cancer mortality. Here, we aimed to identify a melanoma-specific circulating microRNA signature and assess its value as a diagnostic tool.
METHODS
The study consisted of a discovery phase and two validation phases. Circulating plasma extracellular vesicles (pEV) associated microRNA profiles were obtained from a discovery cohort of metastatic melanoma patients and normal subjects as controls. A pEV-microRNA signature was obtained using a LASSO penalized logistic regression model. The pEV-microRNA signature was subsequently validated both in a publicly available dataset and in an independent internal cohort.
RESULTS
We identified and validated in three independent cohorts a panel of melanoma-specific circulating microRNAs that showed high accuracy in differentiating melanoma patients from healthy subjects with an area under the curve (AUC) of 1.00, 0.94 and 0.75 respectively. Investigation of the function of the pEV-microRNA signature evidenced their possible immune suppressive role in melanoma patients.
CONCLUSIONS
We demonstrate that a blood test based on circulating microRNAs can non-invasively detect melanoma, offering a novel diagnostic tool for improving standard care. Moreover, we revealed an immune suppressive role for melanoma pEV-microRNAs.
Identifiants
pubmed: 36243798
doi: 10.1186/s12967-022-03668-1
pii: 10.1186/s12967-022-03668-1
pmc: PMC9571479
doi:
Substances chimiques
Biomarkers, Tumor
0
Circulating MicroRNA
0
MicroRNAs
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
469Informations de copyright
© 2022. The Author(s).
Références
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
N Engl J Med. 2019 Aug 15;381(7):626-636
pubmed: 31166680
Int J Biol Sci. 2022 Jan 24;18(4):1491-1507
pubmed: 35280687
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Cancers (Basel). 2020 Jun 25;12(6):
pubmed: 32630542
Nat Rev Genet. 2019 Feb;20(2):71-88
pubmed: 30410101
Cell. 2015 May 21;161(5):1046-1057
pubmed: 26000481
F1000Res. 2014 Aug 05;3:183
pubmed: 26500764
BMC Cancer. 2018 Apr 18;18(1):439
pubmed: 29669525
Cell Metab. 2019 Oct 1;30(4):656-673
pubmed: 31447320
Clin Cancer Res. 2021 Sep 1;27(17):4737-4745
pubmed: 34112708
Lancet Oncol. 2019 Sep;20(9):1239-1251
pubmed: 31345627
Nat Biotechnol. 2017 Sep;35(9):872-878
pubmed: 28829439
Mol Med Rep. 2016 Jan;13(1):994-1002
pubmed: 26647877
J Cell Physiol. 2019 Feb 5;:
pubmed: 30723916
J Extracell Vesicles. 2018 Feb 15;7(1):1435138
pubmed: 29511460
EMBO Mol Med. 2012 Mar;4(3):143-59
pubmed: 22351564
Nat Rev Mol Cell Biol. 2018 Apr;19(4):213-228
pubmed: 29339798
J Clin Invest. 2016 Apr 1;126(4):1139-43
pubmed: 27035805
BMC Bioinformatics. 2011 Mar 17;12:77
pubmed: 21414208
Cell J. 2020 Oct;22(3):386-393
pubmed: 31863665
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Nat Biotechnol. 2008 Apr;26(4):462-9
pubmed: 18362881
Oncogene. 2013 Mar 21;32(12):1549-59
pubmed: 22641218
PLoS One. 2017 Dec 6;12(12):e0189165
pubmed: 29211799
Cancers (Basel). 2020 Nov 13;12(11):
pubmed: 33202891
Signal Transduct Target Ther. 2016 Jan 28;1:15004
pubmed: 29263891
J Clin Med. 2015 Dec 17;4(12):2012-27
pubmed: 26694476
Clin Cancer Res. 2019 Dec 15;25(24):7351-7362
pubmed: 31530631
J Exp Med. 2019 May 6;216(5):1091-1107
pubmed: 30975896
Cell Death Differ. 2016 Mar;23(3):484-95
pubmed: 26337669
Eur J Cancer. 2020 Feb;126:33-44
pubmed: 31901705
Life Sci Alliance. 2019 Mar 7;2(2):
pubmed: 30846484
Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9
pubmed: 12434020
Clin Res Hepatol Gastroenterol. 2020 Feb;44(1):101-114
pubmed: 31255531
EBioMedicine. 2020 Dec;62:103119
pubmed: 33242827
Biosci Rep. 2018 Jun 21;38(3):
pubmed: 29871972
Melanoma Res. 2018 Aug;28(4):295-303
pubmed: 29750752
Neoplasma. 2020 Mar;67(2):267-276
pubmed: 31847527
Biomed Pharmacother. 2019 Jul;115:108944
pubmed: 31082771
Arch Pathol Lab Med. 2014 Jun;138(6):828-32
pubmed: 24878024
Cell. 1996 Aug 23;86(4):531-42
pubmed: 8752208
Clin Cancer Res. 2021 Oct 1;27(19):5225-5235
pubmed: 34158360
Cancers (Basel). 2020 Feb 13;12(2):
pubmed: 32069911
Drug Deliv Transl Res. 2014 Feb;4(1):19-30
pubmed: 25786615
Front Genet. 2013 May 24;4:94
pubmed: 23745127
Sci Rep. 2016 Jan 20;6:19413
pubmed: 26786760
Sci Rep. 2020 Jan 9;10(1):92
pubmed: 31919420
Bioinformatics. 2009 Dec 15;25(24):3325-6
pubmed: 19808880
Wiley Interdiscip Rev RNA. 2021 Nov;12(6):e1662
pubmed: 33998154
Med Sci (Basel). 2021 Oct 20;9(4):
pubmed: 34698235
Cell Death Dis. 2020 Mar 30;11(3):210
pubmed: 32231206
Med Oncol. 2016 Aug;33(8):88
pubmed: 27389544
Cancers (Basel). 2021 Jun 09;13(12):
pubmed: 34207514